Business
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress
About this update from Alzamend Neuro, Inc.
[{"type":"image","alt":"Alzamend Neuro, Inc.","displaySize":"","headline":null,"caption":"Alzamend Neuro, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/beaa4f3451e46424f3f01617d10e3695"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_uEJOJXjxPyeOYcOwc1Xqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/beaa4f3451e46424f3f01617d10e3695","width":300,"height":71}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in MDD subjects","length":183,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":183,"olType":false},{"type":"text","content":"ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with MDD in the fourth quarter of 2025. This study follows the successful completion of a head coil by Tesla Dynamic Coils BV, a key component of the clinical trial.","length":619,"tagName":"p"},{"type":"image","alt":"Important Statistics About Major Depressive Disorder in the USAAll rights reserved; proprietary content owned by Alzamend Neuro, Inc.","displaySize":"","headline":null,"caption":"Important Statistics About Major Depressive Disorder in the USAAll rights reserved; proprietary content owned by Alzamend Neuro, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":1080,"url":"https://media.zenfs.com/en/globenewswire.com/e35d09ba4bfa7f01133c509bfe497332"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oEQOXecc.u._y9KhGeRkTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTU0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e35d09ba4bfa7f01133c509bfe497332","width":960,"height":540},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/n84hMPdGzRC2LEfbFmRGfQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MD...